Press Release

Medtronic Launches the Entrust(TM) Delivery System in the United States

Medtronic, Inc.

New System Provides an Easy to Use, Accurate and Controlled, One-Handed Stent Delivery System When Treating Patients with Peripheral Arterial Disease

DUBLIN - August 5, 2015 - Medtronic plc (NYSE: MDT) today announced the launch of its Entrust(TM) delivery system in the United States. The new Entrust delivery system enables physicians to place Medtronic's EverFlex(TM) self-expanding peripheral stent, while maintaining a low profile and providing the ease of a one-handed device.

"The Entrust delivery system allows me to confidently deliver the EverFlex stent with control and ease, ensuring precise placement of the stent even in difficult, complex or hard to reach lesions," said Dr. George Meier, chief of Vascular Surgery, University of Cincinnati Medical Center.

The Entrust delivery system deploys the EverFlex stent to re-open narrowed (stenotic) regions of the superficial femoral and proximal popliteal arteries that supply blood to the legs. Narrowing of these arteries is associated with a condition known as peripheral arterial disease (PAD), where plaque builds along lining of the arteries, blocking blood flow to the legs.

"The Entrust delivery system is a great example of how industry and physicians can partner to deliver game-changing technology," said Luke Marone, M.D., chief Cardiovascular Surgery, UPMC Passavant Hospital, director of Peripheral Intervention UPMC HVI. "The low profile, long catheter option, and one-handed, triaxial delivery system put the Entrust delivery system in a class of its own when it comes to peripheral vascular stents."

The Entrust delivery system provides control and precision with its 5 F triaxial delivery system and its distinctive combination of features, including 0.035" guidewire compatibility, longer catheter lengths, and a broad stent matrix. The Entrust delivery system uses the EverFlex stent, which has been clinically proven to be safe and effective in treating long, complex and highly calcified lesions.

"Based on physician feedback and procedural observation, we developed an easy to use one-handed delivery system to increase the stent delivery options in our portfolio," said Brian Verrier, vice president and general manager of Peripheral Vascular, a business in Medtronic's Aortic and Peripheral Vascular division. "Both the Entrust delivery system and the EverFlex(TM) Stent with the pin-pull delivery system provide enhanced choice and treatment solutions for peripheral arterial disease."  

In collaboration with leading clinicians, researchers and scientists, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular diseases and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers worldwide.

ABOUT MEDTRONIC
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is the global leader in medical technology -- alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

- end -

Contacts:
Krystin Hayward
Public Relations
+1-508-261-6512

Ryan Weispfenning
Investor Relations
+1-763-505-4626


HUG#1943576
X